A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lori Styles
Pharmacyclics LLC.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
71 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site Reference Id/investigator #0503
Woolloongabba, Queensland, Australia
- Site Reference Id/investigator# 0650
Adelaide, South Australia, Australia
- Site Reference Id/investigator# 0888
Ballarat, Victoria, Australia
- Site Reference Id/investigator# 0193
Box Hill, Victoria, Australia
- Site Reference Id/investigator# 0633
Fitzroy, Victoria, Australia
- Site Reference Id/investigator# 0170
Heidelberg, Victoria, Australia
- Site Reference Id/investigator# 0352
Linz, Austria
- Site Reference Id/investigator# 0869
Salzburg, Austria
- Site Reference Id/investigator# 0559
Leuven, Belgium
- Site Reference Id/investigator# 0850
Turnhout, Belgium
- Site Reference Id/investigator# 018
Edmonton, Alberta, Canada
- Site Reference Id/investigator# 0564
Hradec Králové, Czechia
- Site Reference Id/investigator# 0854
Prague, Czechia
- Site Reference Id/investigator# 0769
Pessac, Gironde, France
- Site Reference Id/investigator# 0520
Nantes, Loire Atlantique, France
- Site Reference Id/investigator# 0775
Vandœuvre-lès-Nancy, Meurthe Et Moselle, France
- Site Reference Id/investigator# 0855
Bayonne, Pyrenees Atlantiques, France
- Site Reference Id/investigator# 0573
Haifa, Israel
- Site Reference Id/investigator# 0577
Jerusalem, Israel
- Site Reference Id/investigator# 0579
Jerusalem, Israel
- Site Reference Id/investigator# 0575
Petah Tikva, Israel
- Site Reference Id/investigator# 0856
Tel Aviv, Israel
- Site Reference Id/investigator# 0875
Ẕerifin, Israel
- Site Reference Id/investigator# 0860
Florence, Italy
- Site Reference Id/investigator# 0523
Milan, Italy
- Site Reference Id/investigator# 0581
Milan, Italy
- Site Reference Id/investigator# 0584
Milan, Italy
- Site Reference Id/investigator# 0524
Modena, Italy
- Site Reference Id/investigator# 0582
Novara, Italy
- Site Reference Id/investigator# 0732
Roma, Italy
- Site Reference Id/investigator# 0859
Siena, Italy
- Site Reference Id/investigator# 0663
Auckland, New Zealand
- Site Reference Id/investigator# 662
Auckland, New Zealand
- Site Reference Id/investigator# 0586
Hamilton, New Zealand
- Site Reference Id/investigator# 0592
Brzozów, Poland
- Site Reference Id/investigator# 0531
Lodz, Poland
- Site Reference Id/investigator# 0708
Nizhny Novgorod, Russia
- Site Reference Id/investigator# 0707
Ryazan, Russia
- Site Reference Id/investigator# 0881
Saint Petersburg, Russia
- Site Reference Id/investigator# 710
Saint Petersburg, Russia
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Oct 2014
- Primary completion
- 26 Mar 2018
- Completion
- 3 Sept 2019
- Last update posted
- 21 Sept 2020
- Registered enrollment
- 229
- Registry id
- NCT02264574
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.